These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 11343881)

  • 1. A new 5-aminosalicylic acid multi-unit dosage form for the therapy of ulcerative colitis.
    Rudolph MW; Klein S; Beckert TE; Petereit H; Dressman JB
    Eur J Pharm Biopharm; 2001 May; 51(3):183-90. PubMed ID: 11343881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preparation and evaluation of colon adhesive pellets of 5-aminosalicylic acid.
    Xu M; Sun M; Qiao H; Ping Q; Elamin ES
    Int J Pharm; 2014 Jul; 468(1-2):165-71. PubMed ID: 24746693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and in vitro evaluation of mesalamine delayed release pellets and tableted reservoir-type pellets.
    Bendas ER; Christensen JM; Ayres JW
    Drug Dev Ind Pharm; 2010 Apr; 36(4):393-404. PubMed ID: 19740039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioadhesive pellets increase local 5-aminosalicylic acid concentration in experimental colitis.
    Bautzová T; Rabišková M; Béduneau A; Pellequer Y; Lamprecht A
    Eur J Pharm Biopharm; 2012 Jun; 81(2):379-85. PubMed ID: 22386911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of 5-ASA layered or matrix pellets coated with a combination of ethylcellulose and eudragits L and s in the treatment of ulcerative colitis in rats.
    Sardou HS; Sadeghi F; Garekani HA; Akhgari A; Hossein Jafarian A; Abbaspour M; Nokhodchi A
    Int J Pharm; 2023 Jun; 640():122981. PubMed ID: 37120124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Release of 5-Aminosalicylic Acid (5-ASA) from Mesalamine Formulations at Various pH Levels.
    Abinusawa A; Tenjarla S
    Adv Ther; 2015 May; 32(5):477-84. PubMed ID: 25951927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of Pharmaceutical Formulation on the Mucosal Concentration of 5-Aminosalicylic Acid and N-Acetylmesalamine in Japanese Patients with Ulcerative Colitis.
    Yamamoto Y; Masuda S; Nakase H; Matsuura M; Maruyama S; Hisamatsu T; Suzuki Y; Matsubara K
    Biol Pharm Bull; 2019 Jan; 42(1):81-86. PubMed ID: 30369547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimization study of combined enteric and time-dependent polymethacrylates as a coating for colon targeted delivery of 5-ASA pellets in rats with ulcerative colitis.
    Shahdadi Sardou H; Akhgari A; Mohammadpour AH; Beheshti Namdar A; Kamali H; Jafarian AH; Afrasiabi Garekani H; Sadeghi F
    Eur J Pharm Sci; 2022 Jan; 168():106072. PubMed ID: 34774715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dissolution of Commercially Available Mesalamine Formulations at Various pH Levels.
    Tenjarla S
    Drugs R D; 2015 Jun; 15(2):211-5. PubMed ID: 26115756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel pH-sensitive hydrogels for 5-aminosalicylic acid colon targeting delivery: in vivo study with ulcerative colitis targeting therapy in mice.
    Bai XY; Yan Y; Wang L; Zhao LG; Wang K
    Drug Deliv; 2016 Jul; 23(6):1926-32. PubMed ID: 25693641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiparticulate drug delivery system of aceclofenac: development and in vitro studies.
    Shavi GV; Nayak U; Averineni RK; Arumugam K; Meka SR; Nayanabhirama U; Sureshwar P
    Drug Dev Ind Pharm; 2009 Feb; 35(2):252-8. PubMed ID: 18798090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Statistical optimization of indomethacin pellets coated with pH-dependent methacrylic polymers for possible colonic drug delivery.
    Akhgari A; Afrasiabi Garekani H; Sadeghi F; Azimaie M
    Int J Pharm; 2005 Nov; 305(1-2):22-30. PubMed ID: 16236475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Time- and pH-dependent colon-specific drug delivery for orally administered diclofenac sodium and 5-aminosalicylic acid.
    Cheng G; An F; Zou MJ; Sun J; Hao XH; He YX
    World J Gastroenterol; 2004 Jun; 10(12):1769-74. PubMed ID: 15188503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tailoring the mucoadhesive and sustained release characteristics of mesalamine loaded formulations for local treatment of distal forms of ulcerative colitis.
    Ali HS; Hanafy AF; El Achy SN
    Eur J Pharm Sci; 2016 Oct; 93():233-43. PubMed ID: 27503459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mesalamine with MMX technology for the treatment of ulcerative colitis.
    Schreiber S; Kamm MA; Lichtenstein GR
    Expert Rev Gastroenterol Hepatol; 2008 Jun; 2(3):299-314. PubMed ID: 19072380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral 5-aminosalicylic acid therapy for mild-to-moderate ulcerative colitis.
    Olmstead J
    J Am Acad Nurse Pract; 2010 Nov; 22(11):586-92. PubMed ID: 21054632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eudragit FS 30 D: a new pH-sensitive polymer covering for mesalamine.
    Potestà P
    Eur Rev Med Pharmacol Sci; 2001; 5(1):30. PubMed ID: 11860220
    [No Abstract]   [Full Text] [Related]  

  • 18. In-vitro characterization of 5-aminosalicylic acid release from MMX mesalamine tablets and determination of tablet coating thickness.
    Tenjarla S; Abinusawa A
    Adv Ther; 2011 Jan; 28(1):62-72. PubMed ID: 21088944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Site-specific delivery of anti-inflammatory drugs in the gastrointestinal tract: an in-vitro release model.
    Klein S; Stein J; Dressman J
    J Pharm Pharmacol; 2005 Jun; 57(6):709-19. PubMed ID: 15969925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective drug delivery to the colon using pectin-coated pellets.
    He W; Qing D; Cao DY; Fan LF; Xiang B
    PDA J Pharm Sci Technol; 2008; 62(4):264-72. PubMed ID: 19174955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.